All news

Kimberly-Clark eyes five-part bond sale for $36B Kenvue deal

Alpha Vantage · Quartz · · AI-summarised by FinFlash

Kimberly-Clark is considering a five-part bond sale to help finance its acquisition of Kenvue, the maker of Tylenol. JPMorgan Chase is coordinating investor calls for the potential offering, which could mature in two to ten years. The bond sale aims to replace bridge financing for the $36 billion deal, of which $6.7 billion is cash.

Read original source

KMB company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.